Get the Stockscreener App
12.44
0.60%
0.010
Neogenomics Inc stock is traded at $12.44, with a volume of 589.55K.
It is up +0.60% in the last 24 hours and up +1.83% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$12.43
Open:
$12.43
24h Volume:
589.55K
Relative Volume:
0.26
Market Cap:
$1.61B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-20.06
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
-1.07%
1M Performance:
+1.83%
6M Performance:
+98.81%
1Y Performance:
-16.86%
1-Day Range:
$12.04
$12.67
1-Week Range:
$12.04
$13.29
52-Week Range:
$4.72
$15.32
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
12.48 | 1.61B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
624.82 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.18 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
694.75 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.19 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.71 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 - BioSpace
NeoGenomics: Distribution Moat In Community Oncology (NASDAQ:NEO) - Seeking Alpha
Should NeoGenomics’ CFO Transition and Early 2025 Revenue Signals Require Action From NEO Investors? - simplywall.st
Published on: 2026-01-25 10:30:50 - baoquankhu1.vn
Don't Ignore The Insider Selling In NeoGenomics - Sahm
NeoGenomics (NASDAQ:NEO) COO Sells 22,128 Shares of Stock - MarketBeat
Neogenomics pres. Stone sells $277k in NEO stock By Investing.com - Investing.com Nigeria
Neogenomics pres. Stone sells $277k in NEO stock - Investing.com
Anatomic Pathology Market Innovations and Key Players: Agilent - openPR.com
Volume Report: Why is NeoGenomics Inc stock going upEarnings Growth Summary & Smart Money Movement Tracker - baoquankhu1.vn
NeoGenomics, Inc. (NEO) Stock Analysis: Unpacking a 12.81% Upside Potential Amidst Healthcare Diagnostics Growth - directorstalkinterviews.com
Is NeoGenomics Inc. stock overvalued or fairly pricedFinancial Sector Performance & Target Triple-Digit Stock Opportunities - bollywoodhelpline.com
Aug Sentiment: Why is NeoGenomics Inc stock going upRate Cut & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
How NeoGenomics’ (NEO) CFO Transition and Double‑Digit Revenue Guidance Has Changed Its Investment Story - simplywall.st
Pullback Watch: Should you buy the dip on NeoGenomics IncJuly 2025 Trade Ideas & Smart Swing Trading Alerts - baoquankhu1.vn
NeoGenomics (NASDAQ:NEO) Raised to Strong-Buy at Zacks Research - MarketBeat
What’s the analyst consensus on NeoGenomics Inc.2025 Pullback Review & Weekly Sector Rotation Insights - bollywoodhelpline.com
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and NeoGenomics (NEO) - The Globe and Mail
Aug Volume: Is NeoGenomics Inc stock undervalued right nowQuarterly Profit Summary & Fast Gain Stock Trading Tips - baoquankhu1.vn
NeoGenomics names incoming CFO amid revenue growth - Gulfshore Business
NeoGenomics, Inc. (NEO) Stock Analysis: Assessing A 16.59% Potential Upside - DirectorsTalk Interviews
NeoGenomics forecasts 11% revenue growth for Q4 2025, names new CFO - Investing.com Nigeria
NeoGenomics (NASDAQ:NEO) Shares Down 7.4%Here's What Happened - MarketBeat
NeoGenomics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
NeoGenomics, Inc. Announces Executive Changes - marketscreener.com
Fort Myers-based NeoGenomics expects big revenue increase for 2025 - news-press.com
NeoGenomics (NASDAQ:NEO) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors - The National Law Review
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue - PharmiWeb.com
NeoGenomics sees Q4 revenue of about $190M - MSN
NeoGenomics prelim Q4 revenue slightly beats estimates, names insider as CFO - TradingView
NeoGenomics announces board changes to support future growth - MSN
How NeoGenomics Inc. stock reacts to oil prices2025 Biggest Moves & Weekly Return Optimization Plans - Улправда
Will NeoGenomics Inc. stock attract more institutional investorsMarket Risk Analysis & Daily Risk Controlled Trade Plans - Улправда
Will NeoGenomics Inc. stock benefit from infrastructure spending2025 Macro Impact & Fast Moving Trade Plans - Улправда
Neogenomics Shares Surge on Strategic and Legal Developments - AD HOC NEWS
Will NeoGenomics Inc. stock outperform international peersQuarterly Market Summary & Smart Money Movement Alerts - Улправда
A Look At NeoGenomics (NEO) Valuation After Recent Share Price Momentum Shift - Yahoo Finance
NeoGenomics, Inc. (NEO) Investor Outlook: Diagnostic Leader With 18% Upside Potential - DirectorsTalk Interviews
NeoGenomics to Present at 44th Annual J.P. Morgan Healthcare Conference - Intellectia AI
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The AI Journal
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
NeoGenomics Adds Diagnostics Executive Jack Kenny To Board - Pulse 2.0
HighMark Wealth Management LLC Has $3.09 Million Position in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics Announces Board Changes to Support Future Growth - The Globe and Mail
NeoGenomics appoints diagnostics veteran Jack Kenny to board By Investing.com - Investing.com Nigeria
NeoGenomics, Inc. (NEO) Stock Analysis: Exploring a 13% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews
Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):